HB 870: INSURANCE/HEALTH: Provides relative to formulary placement and cost-sharing requirements for certain generic drugs and biosimilars (EN NO IMPACT See Note)
HB 870 status: Enacted — Signed by the Governor. Becomes Act No. 907 (updated Jun 12, 2026).
What this bill does
Overall score
Bill summary
OfficialINSURANCE/HEALTH: Provides relative to formulary placement and cost-sharing requirements for certain generic drugs and biosimilars (EN NO IMPACT See Note). Currently in House.
Key analysis
Impact analysis
Environment
Benefits
- No direct effect identified
Risks
- No direct effect identified
Economy
Benefits
- Reduces consumer out-of-pocket medical costs
- Encourages use of lower-cost generic alternatives
Risks
- Potential administrative compliance costs for insurance providers
- Limitations on insurer formulary design flexibility
Society
Benefits
- Improves patient access to affordable biosimilars
- Supports transparency in drug cost-sharing
Risks
- Implementation relies on insurance plan adherence
How trustworthy & consequential it is
Source
OpenStates
Confidence
lowlow
Analysis status
OpenStates summary
LegiScan returned a PDF-only document. PDF extraction is not enabled in this build, so the pipeline used a safer fallback.
Analysis is based on limited summary text
Where it stands
Introduced
CompleteCommittee
CompleteFloor
CompleteGovernor
CompleteEnacted
CompleteHow it affects your district
Set your location
Add your district to see how this bill may affect your community and who to contact.
Take action
Contact your representatives
Let them know how you feel about this bill.
Share your view
Join the discussion and see what others are saying.
Track this bill
Stay updated on progress and changes.